Merck Animal Health has announced that the Sequivity IAV-S NA vaccine is commercially available as part of its swine product portfolio. The company received license approval for the vaccine from the USDA in 2022.

The Sequivity IAV-S NA vaccine is the first commercial vaccine that uses only the influenza neuraminidase surface antigen to vaccinate pigs against influenza strains H1N1, H1N2 and H3N2. The NA RNA particles in the vaccine are produced using the innovative Sequivity platform technology from Merck Animal Health that previously has been used to target existing and emerging swine pathogens.

“Merck Animal Health is excited to bring this important innovation to our customers as it demonstrates our mission to bring forward solutions to solve swine disease challenges and improve animal health,” said Channing Sebo-Decker, D.V.M., swine technical services veterinarian, Merck Animal Health. “The Sequivity IAV-S NA vaccine represents a novel technological advancement and creates a new tool for influenza control programs.”

The frozen vaccine is mixed with Microsol Diluvac Forte adjuvant at point of use. Pigs can be vaccinated as early as three days of age followed by a booster three weeks later. The duration of the immunity against the H1N1 subtype is at least 12 weeks post-booster dose.

The licensing trials demonstrated that the vaccine was safe and significantly reduced IAV-associated lung lesions and nasal shedding against five challenge strains from the H1N1, H1N2 and H3N2 subtypes.

Sequivity IAV-S NA vaccine is available in 50-dose and 250-dose presentations. To learn more about Merck's portfolio of swine health products and vaccines, visit the website.